Only first 10,000 results will be saved in the file.
No item is selected. Use checkboxes to select search results.
Displaying 1-1 of 1 results.
{{ selectedCountPage }} items selected on this page,{{ selectedCountPage }} item selected on this page,{{ selectedCountTotal }} item in total{{ selectedCountTotal }} items in total
The objective of this randomized, double-blind, placebo controlled study is to test the hypothesis that the addition of omega-3 fatty acids would improve psychopathology in subjects with schizophrenia treated with typical antipsychotics. A total of 36 patients with chronic DSM-IV-diagnosed schizophrenia will receive chlorpromazine (1000 mg/day or equivalent dose of other typical antipsychotics) combined with either placebo or 3000 mg/day of omega-3 for 6 months. Efficacy will be defined as the change from baseline to endpoint in score on the Positive and Negative Syndrome Scale (PANSS).